We didn’t execute a tumor biopsy in account from the patient’s protection. in whom the percentage of tumor cells with membranous PD-L1 staining (tumor percentage
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
We didn’t execute a tumor biopsy in account from the patient’s protection. in whom the percentage of tumor cells with membranous PD-L1 staining (tumor percentage